UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 17, 2015

 

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of

Incorporation)

 

 

 

Registrant’s telephone number, including area code:  (301) 838-2500

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01              Other Events.

 

On June 17, 2015, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release announcing that it had received notice that, effective following the close of trading on June 15, 2015, New Enterprise Associates (“NEA”) distributed an aggregate of 3,921,000 shares of Supernus Pharmaceuticals common stock (“common stock”) to its partners.  A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

On June 17, 2015, Supernus issued a press release announcing that the correct number of shares of common stock distributed to NEA’s partners was 3,000,000.   A copy of this press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

 

Item 9.01              Financial Statements and Exhibits.

 

(d)           Exhibits

 

The following documents are furnished as Exhibits pursuant to Item 8.01 hereof:

 

Exhibit 99.1 — Press Release Dated June 17, 2015 announcing receipt of NEA’s share distribution notice.

Exhibit 99.2 — Press Release Dated June 17, 2015 announcing the corrected number of shares of common stock distributed by NEA.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	SUPERNUS PHARMACEUTICALS, INC.
DATED: June 19, 2015	By:	/s/	Gregory S. Patrick
			Gregory S. Patrick
			Vice-President and Chief Financial Officer

 

3

 

EXHIBIT INDEX

 

 

4